Recent advances in liver tissue engineering have encouraged further investigation into the evaluation of therapeutic benefits based on animal disease models. In the present study, liver tissues were engineered in coagulation factor IX knockout (FIX-KO) mice, a mouse model of hemophilia B, to determine if the tissue engineering approach would provide therapeutic benefits. Primary hepatocytes were isolated from the liver of wild-type mice and suspended in a mixture of culture medium and extracellular matrix components. The hepatocyte suspension was injected into the space under the bilateral kidney capsules of the FIX-KO mice to engineer liver tissues. The plasma FIX activities (FIX:C) of the untreated FIX-KO mice were undetectable at any time point. In contrast, the liver tissue engineered FIX-KO mice achieved 1.5-2.5% of plasma FIX activities (FIX:C) and this elevated FIX:C level persisted throughout the 90 day experimental period. Significant FIX mRNA expression levels were found in the engineered liver tissues at levels similar to the wildtype livers. The present study demonstrates that liver tissue engineering could provide therapeutic benefits in the treatment of hemophilia B.
INTRODUCTION
festations of hemophilia B are unpredictable, recurrent, spontaneous bleeding events in various sites including the major joints and internal organs. The bleeding diath-Liver tissue engineering technology has evolved over the past several years, and spurred significant interest as esis of hemophilia B is due to a failure in the production of biologically active coagulation factor IX (FIX) (2) . potential new therapies for several types of liver disease, including genetic deficiencies (14, [18] [19] [20] [21] 23) . Several It has been well established that achieving plasma FIX activities (FIX:C) as low as 1% markedly changes the studies have succeeded in achieving functional persistency of the liver tissues engineered in subcutaneous phenotype of hemophilia B patients from severe to moderate, and greatly improves the symptoms and quality of sites, under the kidney capsule space, or the omentum (8, 9, (15) (16) (17) 19, 20, 28) . Once the liver tissue engineering life of the individuals (2) . Provided that efficient engraftment of hepatocytes as procedures established clinically applicable success, several types of liver diseases will be treated with the well as functional maintenance of clotting factor productions can be achieved in individuals with hemophilia B, tissue engineering procedures. Because most blood clotting factors are produced by the liver (3, 11) , liver tissue cell-based therapy could be a feasible and safe therapeutic option for this disease. Because hepatocytes are the engineering could be a valuable approach in the treatment of inherited clotting factor deficiencies, including primary cell type in the liver involved in FIX clotting factor production (3), hepatocyte-based therapy could be hemophilia A and B. As a proof-of-principle, therapeutic effects were achieved in a mouse model of hemophilia A effective in establishing a novel therapy for hemophilia B. Recent experiments on hepatocyte transplantation engineered liver tissue using wild-type hepatocytes (19) .
Hemophilia B is a recessive X-chromosome-linked into the liver of FIX knockout (FIX-KO) mice achieved 1-2% of FIX:C levels that persisted throughout the ex-congenital bleeding disorder, and its prevalence is approximately 1 in 30,000 males. The main clinical mani-perimental period (26) . These experiments have encour-808 OHASHI ET AL.
aged further investigation of the potential of a tissue en-ume of Engelbreth-Holm-Swarm (EHS) matrix (Matrigel, BD Biosciences, Bedford, MA) to a final ratio of gineering approach for hemophilia B.
The present study was conducted to engineer liver 1.5 × 10 6 hepatocytes/100 µl. A total of 2.4 × 10 6 hepatocytes were transplanted under the bilateral kidney cap-tissues using wild-type hepatocytes under the kidney capsule space of FIX-KO mice. The FIX-related func-sule space of the FIX-KO mice. As an experimental control, several FIX-KO mice received only an abdominal tionality of the engineered liver tissues was assessed, including the plasma FIX activity levels, histological in-incision and did not receive hepatocyte infusion (sham operation). All the surgical procedures were performed vestigations, and FIX mRNA expression of the engineered tissues. The results show that hepatocytes in the under inhalation anesthesia using isofluorane (Forane, Abbott Laboratories, Abott Park, IL). To avoid exces-engineered liver tissues retained the ability to produce FIX, thus resulting in an elevation of FIX:C at 1.0-2.5% sive surgical procedure-related bleeding, all FIX-KO mice including the sham operation group received an of normal plasma levels. The results demonstrate that a liver tissue engineering approach could be a novel thera-IP injection of 0.5 ml pooled normal mouse plasma twice, 30 min prior and 1 h after the tissue engineering peutic option for the treatment of hemophilia B.
surgical procedure (22).
MATERIALS AND METHODS

Coagulation Assay for Plasma FIX Activity Animals
Blood samples were periodically obtained from the Factor IX knock-out (FIX-KO) mice and wild-type retro-orbital plexus of the recipient FIX-KO mice before C57BL/6 mice, which were syngenic to the FIX-KO and after the tissue engineering procedures. The blood mice (originally purchased from The Jackson Laborasamples were immediately anticoagulated with 0.1 vol tory, Bar Harbor, ME), were maintained at the Animal of 3.8% sodium citrate (Sysmex, Kobe, Japan). After Care Center at Nara Medical University. FIX-KO mice, centrifugation, plasma samples were stored at −80°C un-10-15 weeks old, were used as the recipients of the liver til being analyzed. The FIX activity (FIX:C) was quantitissue engineering procedure. Wild-type C57BL/6 mice, fied by one-stage clotting assay based on the activated 10-12 weeks old, were used for hepatocyte donors. All partial thromboplastin time using human FIX-deficient animal studies were conducted under the protocol applasma (Sysmex). Pooled mouse plasma obtained from proved by the Animal Care Committees at Tokyo Womwild-type C57BL/6 mice was used as FIX:C standard. en's Medical University and Nara Medical University.
Each measurement was reported after subtraction of the Mice were placed in cages within a temperature-controlled preoperational baseline FIX:C levels. We have preroom with a 12-h light/dark cycle and ad libitum access viously confirmed that FIX activity levels as low as to food and water. 0.25% of normal mouse plasma could be successfully Hepatocyte Isolation and Purification measured using this assay (26) . The development of neutralizing antibodies against FIX, called FIX inhibitor, Hepatocytes were isolated from wild-type mice using was assessed by the Bethesda method using plasma oba modified two-step collagenase perfusion method as tained at sacrifice time (26) . Briefly, residual FIX:C was previously described (8, 16, 19, 20) . Briefly, the liver was determined after incubating equal volumes of sample primarily perfused with Hank's balanced salt solution plasma with normal mouse plasma at 37°C for 2 h, and (HBSS) (Sigma, St. Louis, MO) containing 0.09% was compared with residual FIX:C of a mixture of FIX EGTA followed by a second perfusion using HBSS conknockout mouse and normal mouse plasma. The prestaining 0.03% collagenase (Sigma) and 5 mM CaCl 2 .
ence of a significant titer of FIX inhibitor was deter-Isolated cells were filtered through a nylon mesh memmined as >0.5 Bethesda unit/ml in this assay. brane and hepatocytes were then purified by centrifuging at 50 × g for 5 min followed by Percoll (GE Health-Histological Analyses care, Buckinghamshire, UK) isodensity centrifugation.
Naive liver specimens and engineered liver tissues Cells were resuspended in DMEM medium (Sigma), and containing the neighboring kidney of the recipient FIXthe cell viability was determined by trypan blue exclu-KO mice were harvested and fixed in 10% buffered sion test. In the present studies, experiments were conformalin. The specimens were also embedded in Tissueducted only when the hepatocyte viabilities exceeded 95%.
Tek O.C.T. compound (Sakura, Torrance, CA). Forma-Liver Tissue Engineering Procedures lin-fixed specimens were paraffin embedded and sliced into 5-µm-thick sections, which were subsequently pro-Hepatocytes were prepared for engineering liver tissue under the kidney capsule space as previously de-cessed for hematoxylin & eosin (H&E) staining or histochemical staining. For the cellular glycogen detection, scribed (8, 15, 17, 19) . In brief, isolated hepatocytes were resuspended with serum-free DMEM with an equal vol-Periodic-Acid-Schiff (PAS) histochemical staining was performed as described previously (19) . To confirm the matrix or sham operation were successfully carried out using FIX-KO mice without any issues related to bleed-staining specificity of the cellular glycogen, serial sections were pretreated with salivary amylase for 60 min ing and all the recipient mice survived throughout the experimental period. At day 90, some of the recipient followed by the same PAS staining procedures.
FIX-KO mice were sacrificed for histological analyses Laser Capture Microdissection (LCM) and mRNA analyses of the engineered liver tissues. The specimens embedded in the Tissue-Tek O.C.T.
Effect of Liver Tissue Engineering on Coagulation FIX compound were sliced into 8-µm-thick sections. The Activity of Hemophilia B sections were then stained with HistoGene LCM Frozen
The FIX activity (FIX:C) in plasma obtained from Section Staining Kit (Arcturus, Mountain View, CA) to FIX-KO mice received liver tissue engineering or sham visualize the engineered liver tissues under the kidney operation was quantified by one-stage clotting assay capsule followed by LCM using a PixCell II LCM Sys- (Fig. 1 ). The FIX:C of the FIX-KO mice prior to the tem (Arcturus). The microdissected tissues were hartissue engineering procedures and the sham operation vested and subjected to total RNA extraction using the groups were consistently below the detection limit PicoPure RNA Isolation Kit (Arcturus). Isolated RNA (0.25% of normal) and thus the values were expressed was amplified using the RiboAmp RNA Amplification as 0. In contrast, the FIX:C of FIX-KO mice that re-Kit (Arcturus) as described previously (28).
ceived liver tissue engineering procedures increased to RT-PCR 1.60 ± 0.55 at week 3, and this elevated FIX:C was sta-One microgram of total RNA was reverse transcribed bly maintained throughout the experimental period. On using Omniscript RT Kit (Qiagen, Hilden, Germany), the other hand, no elevation in the FIX:C levels were and the first-strand cDNA samples were subjected to detected in the sham-operated mice. Overall, the FIX:C PCR amplification in the StepOnePlus Real-Time PCR levels were significantly higher in the recipient mice in Systems (Applied Biosystems, Tokyo, Japan) followed comparison to the levels found in the sham-operated by 2% agarose gel electrophoresis. In addition to the mice at every time point examined (p < 0.05). These re-FIX gene expression, albumin (Alb), ornithine transcarsults indicated that engineering liver tissues by transferbamylase (OTC), and factor VII (FVII) were also anaring nonhemophilic hepatocytes into the individuals lyzed as other gene expression specific to hepatocytes.
with hemophilia B could provide a therapeutic effect by Housekeeping gene, β-actin (ACTB) was used as referde novo production of coagulation factor IX. ence gene. PCR primers for the mouse sequences (FIX, Morphology and Functions of the Engineered FVII, Alb, OTC, and ACTB) were purchased from Taq-Liver Tissues Man Gene Expression Assay (Applied Biosystems,
The kidney tissues were harvested at day 90 to deter-Assay ID: Mm01308427_m1, Mm00487329_m1, Mm mine if the hepatocytes within the engineered liver tis-00802090_m1, Mm00493267_m1, and Mm00607939_ s1, respectively).
Statistical Analysis
Significant differences were tested by repeated measures ANOVA with the use of the ystat2006 software program (Igakutoshoshuppan, Tokyo, Japan). If a probability value of p < 0.05 was obtained, the Dunnett's test was used for comparison for each individual group. A value of p < 0.05 was considered to be significant. Data were presented as the mean ± SD.
RESULTS
Liver Tissue Engineering Procedure Used for the FIX-KO Mice
In order to avoid surgical procedure-related bleeding, transplantation of hepatocytes suspended with EHS-sues maintained healthy morphology and functions. hemophilia B. FIX-KO mice fail to produce any hepatic FIX mRNA, have no circulating FIX protein, bleed ex-H&E staining revealed hepatocytes with large cuboidal shapes and eosinophilic cytoplasm next to the renal tu-cessively with hemostatic events, and display changes of bleeding-induced poor wound healing (11). In order bulus ( Fig. 2A) . Glycogen synthesis, an important liver function, was confirmed by positive PAS staining in the to avoid any surgical process related to bleeding events, normal mouse plasma was injected twice prior and after hepatocytes of the engineered liver tissues (Fig. 2B) . Staining specificity for cellular glycogen in the PAS the tissue engineering procedure. With these plasma replenishments, all the recipient mice tolerated the tissue staining was confirmed by the finding that pretreatment with salivary amylase in the tissue sections diminished engineering surgical procedures. This uneventful process may highlight the simplicity of the tissue engineer-the PAS staining (Fig. 2C) .
The liver-specific mRNA expression levels were as-ing procedures, and they could be reasonably clinically applied to individuals with hemophilia. sessed in the engineered liver tissue specimens. To minimize contamination from the surrounding renal tissues, One of the approaches toward engineering a functional liver tissue has been the infusion of a hepatocyte the engineered liver tissues were selectively dissected from the surrounding kidney tissues by LCM. As shown mixture with extracellular matrix components under the kidney capsule space (15, 17, 19) . The extracellular ma-in Figure 3 , the engineered tissue specimens showed significant expression levels of FIX, FVII, albumin, and trix rich in laminin and type IV collagen contributes to the stable persistence of the hepatic functions including OTC at levels to those of naive healthy livers. Negative FIX signals for samples from the liver and kidney of FIX expression (15). The ability to express clotting factor VIII was documented in previous studies (17, 19) .
FIX-KO mice and positive FIX signal from the liver of wild-type mouse confirmed the detection specificity for
The present study demonstrated that elevated FIX:C in the recipient FIX-KO mice persisted throughout the 90-mouse FIX mRNA in the present assay. No detectable signals were observed for the hepatocyte-specific mRNAs day experimental period. Life-long functional persistence was confirmed in a recent study where the tissue-in the kidney samples. engineered mice were followed for over 450 days, which DISCUSSION is nearly the life span of a normal mouse (unpublished data). The present study demonstrates a relatively simple procedure to engineer liver tissue in hemophilic animals.
Another important determinant in the liver tissue engineering is an ability to undergo regenerative growth, After the infusion of wild-type hepatocytes under the kidney capsule space of FIX-KO mice, engrafted hepa-an important feature of the liver (10). Although the present study did not address to this point, previous investi-tocytes functionally survived and small liver tissues were engineered. The functional performance for the gations established that engineered liver tissues established by the current approach are able to proliferate at FIX production of the engineered liver tissues yielded therapeutic levels of plasma FIX:C. The FIX:C plasma similar levels to the naive livers in face of liver regenerative stimuli (16, 19, 20) . Liver regeneration occurs levels persisted for 90 days, the length of the present study. The present report is the first conclusive therapeu-through two distinct pathways: compensatory regeneration as well as the direct hyperplasia mode of regenera-tic evidence of a liver tissue engineering approach to hemophilia B. tion (10). Previous studies have demonstrated engineered liver tissue specimens are also able to undergo The FIX-KO mouse is a valuable mouse model for both regeneration modes. If it is possible to regulate the the kidney capsule space) may therefore prevent the generation of such coagulation, thus resulting in a higher in vivo liver growth process, engineered liver tissue could be induced to form a larger tissue. Functional con-hepatocyte engraftment rate for the kidney capsule site in comparison to the intrahepatic site. trol of the liver volume will allow liver tissue engineering approach to provide the next generation therapy for It is important to note that the hepatocytes within the engineered tissues showed stable functionality for the hemophilia as well as other forms of liver diseases.
The kidney capsule space offers favorable hepatocyte FIX production throughout the 90 days experimental period. Hepatocytes are known to possess cellular machin-engraftment followed by persistent survival (8, (15) (16) (17) 19) . The kidney site offered higher cell engraftment eries (i.e., posttranslational modification) to produce biologically active forms of clotting factors (1) and thus rate in comparison to intrahepatic transplantation when human hepatocytes were transplanted into NOD/SCID are considered as a suitable candidate for the cell-based therapy for hemophilia (4, 12, 21) . However, given that mice (17) . Successful phenotypic corrections of the disease phenotype of hemophilia A have been described in clotting factor-producing cells could be successfully and stably engrafted in vivo, the cell source may not be lim-experiments where wild-type hepatocytes or coagulation factor-producing cells were transplanted into the kidney ited to wild-type hepatocytes. The tissue engineering approach could also be highlighted by the recently de-capsule (13, 19) . The advantage of the kidney site over the conventional liver site was also documented by veloped cellular technologies to generate coagulation factor-producing cells (5, 7, 13, 25, 27) . Considerable progress Horne et al. (6) describing that humoral and cellular responses to the allogenic hepatocytes engrafted into the has recently been made using gene therapy vector systems. The addition of the FIX expression cassette to the kidney site were blunted in comparison to those responses to the intrahepatic engrafted hepatocytes. Tissue naive FIX expression system of the hepatocytes could theoretically enhance the capacity for the FIX produc-factor-dependent coagulation around the transplanted hepatocytes has also been shown to be one of the mech-tion. It would be reasonable to propose that combining tissue engineering and gene therapy technologies will anisms for poor cell engraftment when hepatocytes are transplanted intrahepatically (24) . We speculate that bring higher levels of therapeutic efficacy. 
